Skip to main
PODD
PODD logo

Insulet (PODD) Stock Forecast & Price Target

Insulet (PODD) Analyst Ratings

Based on 38 analyst ratings
Buy
Strong Buy 32%
Buy 45%
Hold 16%
Sell 0%
Strong Sell 8%

Bulls say

Insulet's positive outlook is supported by its strong sales growth, with global Omnipod sales increasing by 26% year-over-year on an underlying basis in Q4'24, totaling $586 million. The company has also achieved substantial milestones, including reaching over 500,000 active global customers and demonstrating stable retention rates, which signify ongoing business momentum and expanding adoption of its products. Additionally, Insulet's reported sales of $2.07 billion for 2024, a 22% increase year-over-year adjusted for foreign exchange, along with an EPS of $3.24 that surpassed consensus estimates, further underscores its robust financial performance and competitive position in the market.

Bears say

Insulet Corporation's recent financial results indicate a decline in operating and adjusted EBITDA margins, with operating margins decreasing 240 basis points year-over-year and adjusted EBITDA margins down 160 basis points year-over-year, signaling potential challenges in maintaining profitability. Despite forecasting a 16-20% sales growth for 2025, this outlook is tempered by anticipated declines in Drug Delivery revenues and heightened competition from alternative diabetes treatments, which could adversely impact Insulet's market share and overall sales performance. Furthermore, the company's dependence on third-party intermediaries for distribution introduces additional risks that may hinder revenue growth, particularly if these intermediaries favor competing products.

Insulet (PODD) has been analyzed by 38 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 45% recommend Buy, 16% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insulet and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insulet (PODD) Forecast

Analysts have given Insulet (PODD) a Buy based on their latest research and market trends.

According to 38 analysts, Insulet (PODD) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $216.13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $216.13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insulet (PODD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.